The IP estate controlled by Eligo broadly covers compositions of matter and methods relying on the CRISPR-Cas antimicrobials technology, i.e. sequence-specific gene removal and killing of bacteria with CRISPR-Cas.
While some claims are directed to specific bacterial species, specific delivery vector encoding the CRISPR-Cas system or specific CRISPR-Cas system, other types of claims are directed to :
• method of killing with any bacteria, with any type of delivery vector and/or with any CRISPR-Cas system
• pharmaceutical composition comprising any type of delivery vector and/or any CRISPR-Cas system and/or for killing of any type of bacteria
Therefore, any bacteria targeted by any type of DNA payload encoding any CRISPR-Cas system are covered, together with any combination thereof.
In addition, methods involving the treatment of disease with engineered phages encoding a CRISPR-Cas system also fall under the the CRISPR IP controlled by Eligo, as well as pharmaceutical compositions comprising engineered phages encoding a CRISPR-Cas system for killing of bacteria.
Read more about our Gene Editing Platform